Investing.com — TG Therapeutics, Inc. (NASDAQ: TGTX)是一家市值达54亿美元的生物制药公司，过去十二个月收入增长41%。该公司今日分享了两项关于多发性硬化症 (MS)治疗的最新研究发现，重点介绍了患者从其他抗CD20疗法转换至其药物BRIUMVI® (ublituximab-xiiy)的经验。公司执行董事长兼首席执行官Michael S.

The findings reinforce the potential of BRIUMVI in improving patient outcomes for those seeking an alternative to their previous anti-CD20 therapy. Furthermore, the article in CNS DRUGS offers an ...

Briumvi (ublituximab-xiiy) is a brand-name solution for intravenous infusion prescribed for certain forms of multiple sclerosis and clinically isolated syndrome in adults. As with other drugs ...

TG Therapeutics (TGTX) stock spikes as Roche (RHHBY) fails in a Phase 3 trial for a high dose version of its multiple ...

TGTX's Briumvi, despite initial struggles, has shown strong performance by consistently beating earnings estimates, even with competition from Roche's Zunovo. Briumvi's competitive advantages ...

TG Therapeutics, Inc. has announced its schedule for presenting data on BRIUMVI® (ublituximab-xiiy) at the upcoming American Academy of Neurology 2025 annual meeting in San Diego, California ...

(NASDAQ:TGTX) Q4 2024 CEO Michael Weiss highlighted the strong full-year 2024 U.S. revenue of $310 million for BRIUMVI, ...

BofA analyst Alec Stranahan raised the firm’s price target on TG Therapeutics (TGTX) to $11 from $10 and keeps an Underperform rating on the ...

TG Therapeutics will present data on BRIUMVI for relapsing multiple sclerosis at the ACTRIMS forum, February 27 – March 1, 2025. TG Therapeutics, Inc. announced the schedule for presentations on ...

The better-than-expected results were due almost entirely to robust sales of the company's one commercialized drug, multiple sclerosis treatment Briumvi. One development that helped was the drug's ...